Multiple Sclerosis: A T-Cell Disease?

Owen, Samantha; Watson, C. M.; Davison, Alan

doi:10.1016/s0140-6736(88)92457-9

Cited by 7 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numerous studies have suggested a role of T cells eell [25], Class II HLA-DR molecules appear at a in immunpathogenesis of multiple sclerosis (MS) late stage of activation on the surface of T cells [9], during recent years [8,42,49,53,60,62],…”

mentioning

confidence: 99%

CD4⁺, CD8⁺, and CD4⁻ CD8⁻ T Cells in CSF and Blood of Patients with Multiple Sclerosis and Tension Headache

et al. 1990

View full text Add to dashboard Cite

Two-colour flow cytometric analysis was performed on paired samples of peripheral blood (PB) and cerebrospinal fluid (CSF) of patients with untreated multiple sclerosis (MS) and, for reference, subjects with muscular tension headache (TH) using anti-CD3, anti-CD4, anti-CD8, and anti-HLA-DR monoclonal antibodies in different combinations. CD4+/CD8+ T-cell ratio was increased in CSF compared to PB in both MS patients and TH subjects to a similar extent. This was mainly due to higher CD4+ T-cell levels in the CSF compartment. The proportion of HLA-DR+ T cells was higher in CSF than PB in both MS and TH; this increase of DR+ T cells in CSF was more prominent in MS. The level of CD4+ CD8+ T cells, which represent a subset of activated T cells, was not different between CSF and PB, either in MS or in TH. The proportion of CD4- CD8- T cells, which were found generally not to be blast cells, was lower in CSF compared to PB in both patient groups. However, their CSF level was higher and their PB level lower in MS compared to TH. Results point to an accumulation of activated T-helper cells in the CSF of both MS patients and healthy subjects. Fetal-type CD4- CD8- T cells bearing the unusual T-cell receptor gamma/delta seem to be selectively recruited to the CSF of MS patients.

show abstract

mentioning

confidence: 99%

CD4⁺, CD8⁺, and CD4⁻ CD8⁻ T Cells in CSF and Blood of Patients with Multiple Sclerosis and Tension Headache

et al. 1990

View full text Add to dashboard Cite

show abstract

“…MSCs are of interest because they are easily isolated from a small aspirate of bone marrow and readily generate single-cell-derived colonies [3], which can be expanded through as many as 50 population doublings in about 10 weeks [4]. They can differentiate into osteoblasts, adipocytes, chondrocytes [5], myocytes [6], astrocytes, oligodendrocytes, neurons [7] and hepatocytes [8]. For these reasons, the cells are currently being tested for their potential use in cell and gene therapy for a number of diseases [9].…”

Section: Introductionmentioning

confidence: 99%

Therapeutic applications of mesenchymal stroma cells in pediatric diseases: Current aspects and future perspectives

2011

View full text Add to dashboard Cite

SummaryMesenchymal stem cells or stroma cells (MSCs) were recently proven to play various therapeutic roles when used in clinical trials to control various inflammatory, neoplastic and immunologic diseases in children. Clinical trials show some promising results, particularly in diseases where conventional therapy is still ineffective. However, experimental studies sometimes show conflicting results.This review aims to assess the current therapeutic role of MSCs in the control of several pediatric diseases and elaborate on their future applications by reviewing published studies.A review of published studies on this subject based on Pubmed and Medical Subject Heading databases, with search for all relevant articles focusing on results of clinical trials to evaluate the clinical applications of MSCs.The review includes documentation of positive as well as negative applications of MSCs focused on pediatric diseases.MSCs have important immunosuppressive and antifibrotic effects that need to be employed to help patients with diseases for which no conventional management has proven to be effective. They may be also be used as an adjuvant to conventional therapeutic modalities to consolidate recovery.This review sheds light on the significance of the use of MSCs for the treatment of various pediatric diseases and focuses on promising applications. Most of the reported studies agree about the favorable use of MSCs in various diseases; however, more clinical trials, involving larger numbers of patients, need to be conducted in order to refine the outcome of the therapeutic methods and establish standardized protocols.

show abstract

MS: a localized immune disease of the central nervous system

et al. 1989

View full text Add to dashboard Cite

Multiple Sclerosis: A T-Cell Disease?

Cited by 7 publications

References 3 publications

CD4⁺, CD8⁺, and CD4⁻ CD8⁻ T Cells in CSF and Blood of Patients with Multiple Sclerosis and Tension Headache

CD4⁺, CD8⁺, and CD4⁻ CD8⁻ T Cells in CSF and Blood of Patients with Multiple Sclerosis and Tension Headache

Therapeutic applications of mesenchymal stroma cells in pediatric diseases: Current aspects and future perspectives

MS: a localized immune disease of the central nervous system

Contact Info

Product

Resources

About

Multiple Sclerosis: A T-Cell Disease?

Cited by 7 publications

References 3 publications

CD4+, CD8+, and CD4− CD8− T Cells in CSF and Blood of Patients with Multiple Sclerosis and Tension Headache

CD4+, CD8+, and CD4− CD8− T Cells in CSF and Blood of Patients with Multiple Sclerosis and Tension Headache

Therapeutic applications of mesenchymal stroma cells in pediatric diseases: Current aspects and future perspectives

MS: a localized immune disease of the central nervous system

Contact Info

Product

Resources

About

CD4⁺, CD8⁺, and CD4⁻ CD8⁻ T Cells in CSF and Blood of Patients with Multiple Sclerosis and Tension Headache

CD4⁺, CD8⁺, and CD4⁻ CD8⁻ T Cells in CSF and Blood of Patients with Multiple Sclerosis and Tension Headache